Table 2.
Disease characteristics in relation with chemotherapy schedule in relation to chemotherapy schedule
| Disease characteristic | 1w-CDDP (N.114) | 3w-CDDP (N.52) | p | Entire series (%) |
|---|---|---|---|---|
| Histology | 0.125 | |||
| Squamous | 109 (95.6%) | 52 (100%) | 161 (97%) | |
| Other histology | 5 (4.4%) | 0 (0%) | 5 (3%) | |
| Site of the disease | 0.001 | |||
| Oropharynx | 72 (63.2%) | 47 (90.4%) | 119 (71.7%) | |
| Hypopharynx | 23 (20.2%) | 2 (3.8%) | 25 (25.1%) | |
| Larynx | 19 (16.7%) | 3 (5.8%) | 22 (13.3%) | |
| Staging T (TNM 7th Ed) | 0.057 | |||
| T1–T2 | 52 (45.6%) | 32 (61.3%) | 84 (50.6%) | |
| T3–T4 | 62 (54.4%) | 20 (38.5%) | 82 (49.4%) | |
| Staging N (TNM 7th Ed) | 0.024 | |||
| N0 | 16 (14%) | 2 (3.8%) | 18 (10.8%) | |
| N1 | 17 (14.9%) | 6 (11.5%) | 23 (13.9%) | |
| N2 | 80 (70.2%) | 40 (76.9%) | 120 (72.3%) | |
| N3 | 1 (0.9%) | 4 (7.7%) | 5 (3%) | |
| Stage (AJCC 7th Ed) | 0.009 | |||
| II | 5 (4.4%) | 1 (1.9%) | 6 (3.6%) | |
| III | 28 (24.6%) | 3 (5.8%) | 31 (18.7%) | |
| IV | 81 (71.1%) | 48 (92.3%) | 129 (77.7%) | |
| HPV | 0.000 | |||
| Positive | 12 (10.5%) | 32 (61.5%) | 44 (26.5%) | |
| Negative | 11 (9.6%) | 5 (9.6%) | 16 (9.6%) | |
| ND | 91 (79.8%) | 15 (28.8%) | 106 (63.9%) | |
HPV human papilloma virus, TNM tumor, node, metastases, AJCC American Joint Committee on Cancer, 1w-CDDP weekly Cisplatin, 3w-CDDP three-weekly Cisplatin